Pernicious Anemia: Type II Hypersensitivity Reaction

Pernicious anemia is a non-cytotoxic type II hypersensitivity reaction. Autoantibodies target intrinsic factor (IF) or parietal cell antigens (H+/K+ ATPase), leading to vitamin B12 malabsorption.

Mechanism

  • Anti-intrinsic factor antibodies (type 1: block B12 binding; type 2: block IF-B12 complex binding to ileal receptor).
  • Anti-parietal cell antibodies (85–90% of patients) – destroy parietal cells → achlorhydria, IF deficiency.
  • Complement activation and cell-mediated immunity contribute to gastric atrophy.

Distinction from Cytotoxic Type II

Classic cytotoxic type II (e.g., autoimmune hemolytic anemia, ITP) involves antibody-mediated cell lysis via complement or ADCC. Pernicious anemia's primary pathology is functional blockade and atrophy rather than direct lysis of mature cells—hence "non-cytotoxic."

Clinical Features

  • Macrocytic anemia, neuropathy (subacute combined degeneration), glossitis.
  • Diagnosis: low B12, elevated methylmalonic acid/homocysteine, positive antibodies.
  • Treatment: lifelong parenteral (IM) or high-dose oral B12.

Blood Disorders - Related Articles